Navigation Links
Experimental vaccine sets sights on lung cancer
Date:11/30/2010

NEW YORK (Nov. 30, 2010) -- An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

The experimental immunotherapy is intended to prevent cancer recurrence in patients who have already undergone surgical removal of the tumor. The therapy works by exposing the body to a protein called melanoma-associated antigen-A3 (MAGE-A3), normally produced by lung cancer cells.

"By exposing the body to the antigen, the immune system is primed to attack the cancer," says Dr. Nasser Altorki, principal investigator for the study at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he is a thoracic surgeon. He is also director of the Division of Thoracic Surgery and professor of cardiothoracic surgery at Weill Cornell Medical College.

The MAGE-A3 protein is classified as an Antigen-Specific Cancer Immunotherapeutic (ASCI). ASCIs are meant to trigger a specific response, telling antibodies and T-cells of the immune system to recognize and attack the cancer cells in a highly specific manner.

"We are hopeful that if this investigational therapy continues to show encouraging results in clinical trials that it may become a new weapon against non-small cell lung cancer," explains Dr. Joshua R. Sonett, the study's principal investigator at NewYork-Presbyterian Hospital/Columbia University Medical Center, where he is also chief of thoracic surgery and surgical director of the lung transplant program. He is also professor of surgery at Columbia University College of Physicians and Surgeons. "Because the vaccine augments the patient's own immune system, it may be less toxic to normal cells and can be used even when standard chemotherapy is needed. It is a win-win situation."

The most commonly reported side effects are mild local pain, redness, swelling near the site of injection, fever, fatigue and muscle pain.

Patients enrolled in the study are randomly assigned to receive either the vaccine or a placebo. The vaccine is administered through an injection in the arm every three weeks for five injections, then every three months for eight injections.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... New York, NY (PRWEB) , ... May 23, 2016 , ... ... revolutionary, sport-injury preventative testing program for athletes. This is the first time this type ... South California, is being made available to the public in New York. , With ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... 23, 2016 , ... Hadley Institute for the Blind and ... blind or visually impaired, announces the election of Julie S. Tye as its ... Board of Trustees retained Morris & Berger, a firm specializing in non-profit executive ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... , May 19, 2016 ... World Congestive Heart Failure (CHF) Treatment Devices Market - ... CHF treatment devices market would reach $14.8 billion by ... 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate ... period. North America is projected ...
(Date:5/19/2016)... 19, 2016 Research ... "Global In-Vitro Diagnostics (IVD) Market Size, Market ... Key Players, Competitive Strategies and Forecasts, 2012 ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... research report forecasts on In-Vitro Diagnostics (IVD) ...
(Date:5/19/2016)...  IBM,s (NYSE:   IBM )  World Community Grid ... drug candidates to cure Zika, a fast spreading virus ... public health emergency. IBM and a global ... or Android device to join the #OpenZika project. Volunteers ... help; they simply  run an app   on ...
Breaking Medicine Technology: